Between1990and1999,182menweretreatedfornon-seminomatousgermcell testicular tumours. In 24 of them after chemotherapy a residual retroperitoneal masswasremoved.In14ofthemadditionalimmunohistochemical(IHC)examinationsusingantibodiesagainstcytokeratins,vimentin,PLAP,CD30,AFP,βhCG, p53, and MIB-1 were performed. We compared the results of those additional studieswiththeresultsofroutinehistopathologicalexamination.Histologicalassessment revealed most frequently (ca. 54% of cases) non-neoplastic lesions, i.e. fibro-cystic,necroticorinflammatorytumoursandlymphatictissue.Inabout33% ofcases,survivingliveneoplasticcellswerefound.
Introduction
IncidenceoftesticularcancerinPolandis2.4new cases in 100 000 men per year [1] . Analyzing the incidenceinrelationtoage,threedifferentgroupsof thehighestincidencemaybeestablished:infants,25 to40yearolds,andabout60yearolds.Itisimportantthatinyoungmales(20-35yearsold)thiscancer isthemostfrequentone [2] .Meanageofnon-seminomatousgermcelltumourofthetestis(NSGCTT) patients is 25 years. The highest incidence is noted in the Scandinavian countries, Switzerland, Germany and New Zealand, and the lowest in Africa and Asia. In other European countries and in the USA incidencelevelsareaverage.
More and more precise understanding of cancer natural history is being gained from numerous multi-specialiststudies.Newalgorithmsofdifferent sub-types of testicular cancer management are being developed. The key problem is to identify risk and prognostic factors. Recognition of these factors allows one to manage more properly the disease at differentstages. Germcelltumoursofthetestiscompriseagroup ofmorphologicallydiverseneoplasms.Theclassification most frequently used by practitioners and recommendedbytheWHOisshowninTableI.
Non-seminomatousgermcelltumours(NSGCTs) areagroupconstitutingabout50%ofallgermcell tumours of the testis. The majority of them have two or more histological components, being mixed non-seminomas.Insuchcasesthenon-seminomatous component is crucial for prognosis and treatment. Precise, unequivocal and reliable histopathological diagnosisallowsproperstagingandemploymentof proper systemic therapy. It is very important in diagnosis of morphology of both primary tumour of thetestisandtheresidualretroperitonealmassafter chemotherapy removed by retroperitoneal lymphadenectomy. Use of modern immunohistochemical (IHC)markersinhistologicaldiagnosismayimprove its accuracy. The most frequently used IHC markersarecytokeratins,vimentin,PLAP,CD30antigen, AFP,βhCG,p-53protein,andKi-67antigen.
Cytokeratins are structural proteins of epidermal cells. In malignant testicular tumours expression of cytokeratinsistypicalinembryonalcarcinomacells. Among different cytokeratins a positive reaction to cytokeratin8(CK8),cytokeratin18(CK18)andcytokeratin 19 (CK19) is noted. Expression of CK19 isspecificforembryonalcarcinomabecauseitisnot seeninothermalignantgermcelltumoursofthetestis.Otherwise,apositivereactiontoCK8andCK18 isobservedinseminomas,onaverageinabout40% in the literature of the subject. In different articles frequencyofexpressionofCK8andCK18insemino-masvariesfrom0%to73% [3] .
Vimentinisaproteinisolatedfrommurinefibroblasts [4] .Itispositiveinalmostallearly,fetalcell lines [5] .Itisnotacell-specificmarkerbutincorrelationwithothermarkersitmaybeclinicallyhelpful. Itisespeciallyusefulindiagnosisofrenal,endometrial,follicularthyroidandsalivaryglandcancermetastases [6] .
CD30antigenisoneoftheclusterofdifferentia-tiongroupofantigensandisseenmostfrequentlyon thesurfaceofleukocytes [7] .ThemajorityofseminomasdonotshowexpressionofCD30,incontrast to embryonal carcinoma [8] . There is a theory that ifaseminomaisCD30positive,ithadtransformed clinicallyintoembryonalcarcinoma.CD30isause-fultooltodistinguishbetweenembryonalcarcinoma and other germinal tumours, in which it is always negative [9] . PLAP(placentalalkalinephosphatase)physiologicallyisproducedbytheplacentaafter12weeksof pregnancy and is responsible for cellular transport, proliferationanddifferentiationofcells,andmetabolismandgenetranscription [10, 11] .Inthehuman body it may also be produced by cancer cells [12] . PLAPisnotaspecificmarkeroftesticulartumours butitisalsopresentindigestivesystem,pulmonary, breast and female reproductive organ cancers [13, 14] .Activityofthisenzymeisnotedin98%ofsem-inomas and "carcinoma in situ (CIS)" lesions, in 86-97% of embryonal carcinomas and in 85% of yolk sactumours.Normaltesticulartissues,withnoCIS lesions,testicledysgenesis,cryptorchidismortesticularneoplasmevidence,havenoPLAPactivity.This activityinchoriocarcinomaislessthan50% [15] .
βhCG -β subunit of human chorionic gonadotropin-issynthesizedbytrophoblasticcells.βhCG serumleveliselevatedinthemajorityofchoriocarcinomapatientsandinabout10%ofpatientssuffering fromseminoma.DuringanIHCexaminationapositivereactiontoβhCGhelpstoidentifymultinuclear trophoblastic cells in choriocarcinomas, embryonal carcinomasandseminomas.
AFP-α-fetoprotein-isaproteinsecretedmostly bytheyolksacandfetaldigestivesystemepithelial cells.Inadultsitmaybeproducedbyregenerating hepatic cells. AFP serum level is elevated in nearly 75%ofpatientswithnonseminomatousgerminaltu-mours,unlikeinpatientssufferingfromseminomas, inwhichweneverobserveAFPsecretion,sotheexpressionofAFPingerminaltumourcellsindicatesits nonseminomatouscharacter.AFPisalsoamarkerof hepatocellularcarcinoma.
The p53 suppressor gene is located on the short armofchromosome17(17p13).Itisresponsiblefor thecellreplicationcycle;itstopsprogressiontothe S-phase.Mutationsorinactivationsofthep53gene arefrequentlyassociatedwithneoplasmsinhumans [17] .Overexpressionofp53proteinis associated with poor prognosis in different kinds of cancer [18] . Ki-67(MIB-1)isamarkerofproliferativeactivity. The percentage of MIB-1-positive nuclear cells (index)isusedinuropathology,especiallyinbladderand prostatecancerevaluation.Particularlyintheformer, together with p53 protein expression, grading and cellanaplasiamaybepredictivefactorsofrecurrence orprogressionofdisease [19] .Thisindexcanalsobe sometimes useful in uncertain clinical situations in cancerofthetestis.
Objective: histopathological re-evaluation of removedresidualretroperitonealmassinpatientssuffering from non-seminomatous cancers of the testis afterchemotherapyincludingimmunohistochemical markers.
Material and methods
Between1990and1999,182mensufferingfrom nonseminomatous testicular cancers were treated in the Maria Skłodowska-Curie Memorial Institute of Oncology,CracowBranch.Thisgroupwasretrospectivelyanalyzed.
Meanageofpatientswas28.9years. ClinicalstagingwasassessedusingtheTNMclassification(UICC1997)andtheAmericanJointCommittee on Cancer classification. 79.68% of patients wereclassifiedasIAtoIICgrade.82.22%ofpatients had pT1 to pT2 tumours, and 71.98% of patients didnothavedistantmetastases-M0.
Histologicaldiagnosiswasperformedaccordingto criteria in conformity with the WHO classification. Mixednonseminomaswerediagnosedinasmanyas 69.06%ofthosetreated.
Themeanfollow-upperiodwas52.2months.
In the group of 182 patients, 24 of them were qualifiedforsurgerybecauseofpersistenceofaretroperitonealmassafterchemotherapy.Inallpatients retroperitoneal lymphadenectomy with routine microscopicassessmentwasperformed.
In14ofthemremovedspecimenswerere
Slideswerethendeparaffinizedinxylene(30min-utestwice),placedinabsolutealcoholfor5minutes, twice for 5 minutes in 96% alcohol and rinsed in running water. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide solution for 20 minutes. Before staining for cytokeratin AE1/AE3 expressionslideswereinitiallydigestedwithpronase (DAKO, pronase cat. no S2013) for 15 minutes at roomtemperature.SamplespreparedforAFP,βhCG, CD30 antigen, MIB-1, PLAP and two epitopes of the p53 gene product (P53-BP and P53-1801) assessmentwereplacedincitratebufferandsubjected to microwaves twice for 10 minutes. After cooling downtoroomtemperaturesampleswereincubated innormalserum.Thentheywereincubatedwithprimary antibody (Table II) overnight at 4°C followed byaperoxidase-conjugatedpolymer(DAKOEn-Vision/HRP, Rabbit/Mouse, K5007). Finally, the sections were incubated with diaminobenzidine (DAB, 
Results
Agroupof24menwerequalifiedforretroperito-neallymphadenectomyandoperatedonfortheresidualmassafterchemotherapy.Allsurgicalspecimens wereroutinelyhistologicallyexamined.Forthepurposesofourworkteratomahasbeenseparatedfrom othermalignancies.
The most frequent pathological lesions (in about 54% of cases) were non-neoplastic lesions, i.e.: fibro-cystic, necrotic or inflammatory tumours, and lymphatic tissue. However, in nearly 33% of cases, survivingliveneoplasticcellswerefound(TableIII). In12.5%ofcasesteratomawasfound.
Results of the assessment of chosen tissue antigens (cytokeratin, vimentin, PLAP, CD30, α-fetoprotein-AFP and βhCG) and p53 suppressor gene productandKi-67-1(MiB1)antigenexpressionare showninTableIV.
In examined group A -patients with surviving retroperitonealmalignantresiduallesionsdiagnosed inroutinepathologicalexamination-IHCstaining was performed in seven cases. In four of them the second histological and IHC assessment confirmed the diagnosis of a malignancy: embryonal carcinoma, squamous cell carcinoma and choriocarcinoma, twice. In the next three cases teratomas were diagnosed.Embryonalcarcinomatexturewasrecognized byco-expressionofcytokeratins,CD30antigenand AFP.Cellsofchoriocarcinomawereidentifiedbypositive reaction to cytokeratin and βhCG and in one casealsotovimentinandPLAPpresence.Inthecells ofsquamouscarcinomaco-expressionofcytokeratin, vimentinandCD30antigenwasobserved.Theindex ofproliferationMIB-1(Ki-67)inallthesecaseswas highandrangedfrom14.4to78.0%.
IngroupB-patientswithteratoma-histological andIHCevaluationconfirmedthediagnosis.
IngroupC-patientswithnon-neoplasticlesions in routine microscopic examination -histological reassessment and IHC staining of specimens of six patients allowed teratoma to be diagnosed and the previousdiagnosistobechanged.
Cells of benign teratoma in all these IHC examinedcaseswerecharacterizedbyalowindexofproliferationMIB-1(Ki-67)between1.4%and7.6%.
Discussion
Testicular cancer is one of the most promising cancers.Thisisduetoroutinecombinationtherapy combiningsurgery,chemotherapy,andradiotherapy. Postoperative assessment of removed residual tumouroftheretroperitonealspaceisoneofthefactors contributingtothiseffect.Thepracticalquestionis the real influence of modern chemotherapy on the histological texture of retroperitoneal metastases in comparisonwiththemicroscopicpictureofprimary tumourofthetestis.
The segregation of patients based on the evaluation of the surgical specimen into three different groups (group A with persistent malignant cancer tissue, group B with teratocarcinoma and group C patient with nonmalignant changes) influences the patient's prognosis. Our results showed that additional immunohistochemical studies changed the results of routine microscopic examination in some patientsingroupsAandC,andconfirmedallresults ingroupB.
Searchingtheliteraturewecouldhardlyfindapaper concerning a similar matter. What is more, the datathatdescribethechangesinthebiologyofmetastasesafterchemotherapyascomparedtotheprimarytumourarealsolimited.
Itoandothersdescribedacaseoftesticularcancer with malignant transformation in a residual retroperitoneal mature teratoma 8 years after the initial chemotherapy(cisplatin,vinblastine,andbleomycin combination -PVB) for a mixed germ cell tumour [21] .
There is a hypothesis that in nonseminomatous germcelltumour(NSGCT)thepluripotentembryonal carcinoma (EC) cells are the precursors of the manifolddifferentiatedstructuresbutalsodrivethe malignantgrowth.Muelleretal.believethatlackof OCT4expressionindicatescisplatinresistance.They found that post-chemotherapy residual metastatic tumourscanbecomposedofexclusivelyOCT4-negativeEC [22] .
What is more, embryonal carcinoma after chemotherapy can give metastases of different histology to adifferentlocation.SuchacasewasdescribedbyJapaneseresearchers.Fujimuraet al.recognizedmatureteratomainaresidualtumourandseveralyearslaterthey foundarelapseintheretroperitonealspaceandsimulta- 
Conclusions
Additionalimmunohistochemicalstainingforcytokeratin,CD30,AFPandβhCGishelpfulinpatho-logical evaluation of the kind of neoplasm in retroperitonealresidualmassesofgerminaltumoursafter chemotherapy.
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